NuCana plc Seeks Share Subdivision and Highly Dilutive Share Issuance Authority for Critical Financing

summarizeSummary

NuCana plc is seeking shareholder approval for a share subdivision to enable future capital raises and authorization to issue new shares up to £5 million, a potentially highly dilutive move deemed critical for the company's financing and continued operations.

check_boxKey Events

• Proposed Share Subdivision

  Shareholders will vote on a subdivision of existing ordinary and deferred shares to address the inability to issue new ADSs at market value, a necessary step to enable future capital raises.

• Request for Highly Dilutive Share Issuance Authority

  The company is seeking authorization to allot shares up to an aggregate nominal amount of £5 million, with pre-emption rights disapplied, which the board states is critical for financing and continued operations.

• Significant Potential Dilution

  The authorized £5 million share issuance represents a substantial portion of the company's current market capitalization, indicating a high potential for dilution if fully utilized.

• Large Post-Period Option Grant

  Over 3.85 billion ordinary share options were granted to employees, consultants, and directors in January 2026, adding to the significant potential for future dilution.

auto_awesomeAnalysis

NuCana plc is seeking shareholder approval for a significant capital reorganization and new share issuance authority, which the board explicitly states is critical for the company's ability to finance its plans. The proposed share subdivision (Resolutions 8 and 9) is a technical measure to address the current inability to issue new American Depositary Shares (ADSs) at market value, effectively paving the way for future dilutive capital raises. Concurrently, the company is requesting authorization to allot shares up to an aggregate nominal amount of £5 million (Resolutions 10 and 11), with pre-emption rights disapplied. This authorization represents a substantial potential capital raise relative to the company's current valuation, indicating a highly dilutive event if fully utilized. The board's strong recommendation, citing that failure to pass these resolutions would "severely compromise the Company's ability to finance its plans on a continuing basis," underscores the urgency and necessity of these measures for the company's survival. Additionally, a large grant of over 3.85 billion ordinary share options to employees, consultants, and directors occurred in January 2026, further adding to the potential future dilution for existing shareholders. These actions highlight the company's ongoing reliance on equity financing to fund operations, as reflected in its increased net loss of £29.4 million in 2025 and the presence of 'going concern' language in its annual report.